Our Promise

We will help our partners prevail in their mission to develop needed therapies. We will ensure that high-quality development and imperative urgency remains our focus.

How We Help

Launch Therapeutics offers pharmaceutical and biotech partners a variety of innovative models that provide capital, development expertise, and access to additional resources. These models offer an aligned and efficient approach to help finance and develop late-stage therapies and accelerate the path to regulatory approval. Launch Tx’s team of experts bring an unrivaled combination of immense commitment, decades of experience, and enthusiastic passion to their work.

Сapital

Bespoke deal structures taking combination of clinical, regulatory, and commercial risks

Resources

Team with deep clinical and regulatory expertise with access to an expansive network

Acceleration

Disruptive model accelerating clinical development and regulatory timelines

In The News

Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies

Research Triangle Park, North Carolina and Boston, Massachusetts, January 18, 2023 – Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx), a clinical development company, today announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Tx is backed by funds managed by global investment firm Carlyle (NASDAQ: CG) and its life sciences franchise Abingworth.